TTX101 for Malignant Gliomas (Including Glioblastoma!) Earns Orphan Drug Designation
Unsplash: https://unsplash.com/photos/58Z17lnVS4U

TTX101 for Malignant Gliomas (Including Glioblastoma!) Earns Orphan Drug Designation

  Right now, there is an urgent need to identify and develop treatments for people with malignant gliomas, including glioblastoma. Unfortunately, there are limited effective treatment options; these cancers are…

Continue Reading TTX101 for Malignant Gliomas (Including Glioblastoma!) Earns Orphan Drug Designation

Researchers Seek Reason for a Higher Survival Rate in Obese Patients with Pulmonary Arterial Hypertension (PAH)

Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…

Continue Reading Researchers Seek Reason for a Higher Survival Rate in Obese Patients with Pulmonary Arterial Hypertension (PAH)
SAGE-718 for Huntington’s Disease Earns Orphan Drug Designation
source: pixabay.com

SAGE-718 for Huntington’s Disease Earns Orphan Drug Designation

  Currently, there are no FDA-approved treatments designed for cognitive impairment related to Huntington’s disease. However, to improve the lives of those affected, additional research and therapeutic development are urgently…

Continue Reading SAGE-718 for Huntington’s Disease Earns Orphan Drug Designation